[1] Leung D H, Ye W, Schwarzenberg S J, et al. Long-term follow-up and liver outcomes in children with cystic fibrosis and nodular liver on ultrasound in a multi-center study[J]. J Cyst Fibros, 2023, 22: 248-255.
[2] Elborn J S. Cystic fibrosis[J]. Lancet, 2016, 388: 2519-2531.
[3] Scott J, Jones A M, Piper Hanley K, et al. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis[J]. Aliment Pharmacol Ther, 2022, 55: 389-400.
[4] Lewindon P J, Pereira T N, Hoskins A C, et al. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease[J]. Am J Pathol, 2002, 160: 1705-1715.
[5] Sasame A, Stokes D, Bourke B, et al. The impact of liver disease on mortality in cystic fibrosis-A systematic review[J]. J Cyst Fibros, 2022, 21: 202-211.
[6] Boyle M P, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect[J]. Lancet Respir Med, 2013, 1: 158-163.
[7] O'Neal W K, Knowles M R. Cystic fibrosis disease modifiers: complex genetics defines the phenotypic diversity in a monogenic disease[J]. Annu Rev Genomics Hum Genet, 2018, 19: 201-222.
[8] Bartlett J R, Friedman K J, Ling S C, et al. Genetic modifiers of liver disease in cystic fibrosis[J]. JAMA, 2009, 302: 1076-1083.
[9] Boëlle P Y, Debray D, Guillot L, et al. SERPINA1 Z allele is associated with cystic fibrosis liver disease[J]. Genet Med, 2019, 21: 2151-2155.
[10] Stonebraker J R, Pace R G, Gallins P J, et al. Genetic variation in severe cystic fibrosis liver disease is associated with novel mechanisms for disease pathogenesis[J]. Hepatology, 2024, 80: 1012-1025.
[11] Kurabekova R M, Gichkun O E, Tsirulnikova O M, et al. Analysis of the Association between the Tgfb1 Gene Haplotype and Liver Diseases in Children[J]. Acta Naturae, 2023, 15: 75-81.
[12] Wu H, Vu M, Dhingra S, et al. Obliterative Portal Venopathy Without Cirrhosis Is Prevalent in Pediatric Cystic Fibrosis Liver Disease With Portal Hypertension[J]. Clin Gastroenterol Hepatol, 2019, 17: 2134-2136.
[13] Bodewes F, Freeman A J, Weymann A, et al. Towards a standardized classification of the hepatobiliary manifestations in cystic fibrosis (CFHBI): a joint ESPGHAN/NASPGHAN position paper[J]. J Pediatr Gastroenterol Nutr, 2024, 78: 153-165. |
